Retinoic Acid, widely recognized as Tretinoin or All-Trans Retinoic Acid (ATRA), is a cornerstone Pharmaceutical Intermediate with a remarkable range of applications in modern medicine. From its efficacy in dermatological treatments to its critical role in life-saving oncological therapies, the demand for high-purity Retinoic Acid remains consistently high. This compound, typically supplied as a yellow powder, is essential for developing effective health solutions.

In the pharmaceutical industry, Retinoic Acid is valued for its consistent quality and high purity, often exceeding 99%. This stringent standard is vital for its use in medical applications, ensuring both efficacy and safety. The CAS number 302-79-4 serves as a unique identifier for this compound, crucial for quality control and regulatory compliance during drug manufacturing.

One of the most common dermatological uses of Retinoic Acid is in the treatment of acne. It works by promoting skin cell turnover, preventing the blockage of pores, and reducing inflammation, leading to clearer and smoother skin. Its effectiveness has made it a staple ingredient in many topical acne treatments.

Beyond skincare, Retinoic Acid has a profoundly important role in oncology, particularly in the treatment of Acute Promyelocytic Leukemia (APL). This cancer affects the maturation of white blood cells, and ATRA works by inducing the differentiation of these immature cells into mature, functional ones. This targeted action has significantly improved the treatment outcomes for APL patients, cementing ATRA's status as a vital therapeutic agent.

The reliability of Retinoic Acid as a Pharmaceutical Intermediate is further supported by its stable powder form and a shelf life of 2 years, allowing for efficient manufacturing and storage processes. For companies developing pharmaceutical products, securing a consistent supply of high-purity Retinoic Acid is paramount to delivering effective and safe treatments to patients worldwide.